{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T08:29:13Z","timestamp":1783067353408,"version":"3.54.6"},"reference-count":12,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2012,4,16]],"date-time":"2012-04-16T00:00:00Z","timestamp":1334534400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Transplantation"],"published-print":{"date-parts":[[2012,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Long\u2010term allograft survival of antiphospholipid antibody syndrome (<jats:styled-content style=\"fixed-case\">APAS<\/jats:styled-content>) patients as well as patients who have antiphospholipid antibodies but no thrombotic complications remains largely unknown. This study evaluates long\u2010term allograft survival of<jats:styled-content style=\"fixed-case\">APA<\/jats:styled-content>as well as patients with<jats:styled-content style=\"fixed-case\">APAS<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>During the study period from<jats:styled-content style=\"fixed-case\">J<\/jats:styled-content>anuary 1, 1992 through<jats:styled-content style=\"fixed-case\">M<\/jats:styled-content>ay 31, 2009, 1625 patients with<jats:styled-content style=\"fixed-case\">ESRD<\/jats:styled-content>awaiting renal transplants were screened for<jats:styled-content style=\"fixed-case\">APAS<\/jats:styled-content>. Ninety\u2010four (5.8%) of these patients had circulating levels of anticardiolipin antibodies (<jats:styled-content style=\"fixed-case\">ACA<\/jats:styled-content>) and 39 of these patients had documented evidence of clotting disorders and were diagnosed with<jats:styled-content style=\"fixed-case\">APAS<\/jats:styled-content>. Twenty\u2010one patients with<jats:styled-content style=\"fixed-case\">APAS<\/jats:styled-content>received transplants on either low molecular weight (<jats:styled-content style=\"fixed-case\">LMW<\/jats:styled-content>) heparin or<jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>oumadin as anticoagulation therapy. Of 94 patients with only<jats:styled-content style=\"fixed-case\">ACA<\/jats:styled-content>, 46 received renal transplants. Of the remaining 1492 patients, 1285 patients with no evidence of either<jats:styled-content style=\"fixed-case\">ACA<\/jats:styled-content>or<jats:styled-content style=\"fixed-case\">APAS<\/jats:styled-content>received renal transplants.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Ten\u2010yr allograft survival of patients with<jats:styled-content style=\"fixed-case\">APAS<\/jats:styled-content>treated with<jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>oumadin was similar to those treated with<jats:styled-content style=\"fixed-case\">LMW<\/jats:styled-content>heparin (18% vs. 20%,<jats:styled-content style=\"fixed-case\">NS<\/jats:styled-content>). However, those allograft survivals were significantly lower than those patients positive for<jats:styled-content style=\"fixed-case\">ACA<\/jats:styled-content>(28%) alone (<jats:styled-content style=\"fixed-case\">ACA<\/jats:styled-content>vs.<jats:styled-content style=\"fixed-case\">LMW<\/jats:styled-content>heparin or<jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>oumadin p\u00a0=\u00a00.0001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Despite anticoagulation therapies, patients with<jats:styled-content style=\"fixed-case\">APAS<\/jats:styled-content>have lower long\u2010term graft survival than those patients who have circulating<jats:styled-content style=\"fixed-case\">ACA<\/jats:styled-content>but no<jats:styled-content style=\"fixed-case\">APAS<\/jats:styled-content>.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1399-0012.2012.01625.x","type":"journal-article","created":{"date-parts":[[2012,4,17]],"date-time":"2012-04-17T02:25:51Z","timestamp":1334629551000},"page":"853-856","source":"Crossref","is-referenced-by-count":25,"title":["Ten\u2010yr renal allograft survival of patients with antiphospholipid antibody syndrome"],"prefix":"10.1111","volume":"26","author":[{"given":"Smita","family":"Vaidya","sequence":"first","affiliation":[{"name":"Department of Pathology University of Texas Medical Branch Galveston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,4,16]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200004150-00023"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2002.00500.x"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.287.6399.1088"},{"key":"e_1_2_5_5_1","first-page":"1181","article-title":"Renal involvement in primary antiphospholipid syndrome","volume":"19","author":"Amigo MC","year":"1992","journal-title":"J Rheumatol"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000119157.81765.46"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-0012.2002.02024.x"},{"key":"e_1_2_5_8_1","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1399-0012.1998.tb00995.x","article-title":"Relative risk of post transplant renal thrombosis in patients with antiphospholipid antibodies","volume":"12","author":"Vaidya S","year":"1998","journal-title":"Clin Transplant"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199504133321504"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.162.10.1164"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-008-8112-z"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-198503000-00016"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0966-3274(97)80016-0"}],"container-title":["Clinical Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1399-0012.2012.01625.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1399-0012.2012.01625.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T22:47:05Z","timestamp":1742942825000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1399-0012.2012.01625.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,16]]},"references-count":12,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["10.1111\/j.1399-0012.2012.01625.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1399-0012.2012.01625.x","archive":["Portico"],"relation":{},"ISSN":["0902-0063","1399-0012"],"issn-type":[{"value":"0902-0063","type":"print"},{"value":"1399-0012","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,16]]}}}